XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
XTL Biopharmaceuticals Ltd. is set to acquire 100% of the issued and outstanding share capital of THE SOCIAL PROXY LTD., making it a wholly-owned subsidiary. The deal involves a cash payment and equity consideration to the current shareholders of THE SOCIAL PROXY LTD. in exchange for 10,813 ordinary shares. This strategic move is approved by both companies’ boards as being in the best interest of their respective shareholders.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.